/

CTKB

Cytek Biosciences, Inc.Open

5.39+0.08 +1.41%USD

NasdaqGS · as of Oct 13, 15:49 ET · 15m delay

Open

5.26

Prev close

5.31

Day range

5.185.47

52-week range

3.316.21

Volume

1.12M1.02×

Mkt cap

699.96M

P/E ttm

—

Fwd P/E

76.93

EPS ttm

-0.6200

Div yield

0.00%

Earnings

Aug 5, 2026

From 52w high

−13.29%

Price Chart

Yahoo Finance · delayed

CTKBOct 13, 2026O 5.26H 5.47L 5.18C 5.39+0.08 (+1.41%)Vol 1.12M

SMA 504.99
SMA 2004.63

1Y change +39.87% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

CTKB Cytek Biosciences, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +0.09%
1 month: +16.81%
3 months: +16.56%
6 months: +16.56%
Year to date: +6.63%
1 year: +35.98%

Valuation & ownership

Market cap: 699.96M
Enterprise value: 454.67M
P/E (ttm): —
Forward P/E: 76.93
PEG ratio: —
Price / book: 2.17
Price / sales (ttm): 3.39
EV / EBITDA: -11.44
EPS (ttm): -0.6200
EPS (forward): 0.0700
Beta (5y monthly): 1.16
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 129.98M
Float: 102.94M
Short % of float: 5.08%
Short ratio (days): 4.00
Held by insiders: 8.47%
Held by institutions: 62.95%
Avg volume (3m): 1.10M
50-day average: 4.97
200-day average: 4.63
52-week change: +35.98%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 51.3
vs 50-day SMA: +7.84%
vs 200-day SMA: +16.26%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.39%
Realised vol (20d, ann.): 62.3%
From 52-week high: −13.29%
From 52-week low: +62.69%

ANR

Analyst Consensus

4 analysts

Consensus

Buy

2.25 on a 1 (strong buy) – 5 (sell) scale

Mean target

5.56

+3.30% implied

Low 4.75Median 5.00High 7.50

Recommendation trend

Now2 / 2 / 0
1m ago2 / 2 / 0

DES

About Cytek Biosciences, Inc.

Yahoo Finance profile

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Sector: Healthcare
Industry: Medical Devices
Employees: 682
Headquarters

SEAS

Seasonality · CTKB

2021–2026 · monthly returns

Strongest month Nov +22.65%Weakest month May −15.22%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-1.0	-10.4	-2.5	4.3	-8.1	5.7	-4.7	13.3	24.7	-9.6			+6.6%
2025	-20.6	-12.8	-10.7	-7.5	-25.3	22.7	5.9	15.0	-16.2	12.4	44.9	-10.6	−22.2%
2024	-17.2	2.0	-12.9	-10.4	-6.3	-0.9	20.3	-14.5	-3.5	-10.7	32.1	-0.6	−28.8%
2023	18.0	-14.5	-10.8	24.9	-32.0	9.3	4.9	-15.2	-27.4	-23.7	64.8	31.4	−10.7%
2022	-10.8	-6.3	-21.0	-12.3	2.8	10.5	19.3	-9.0	26.4	5.4	-16.9	-20.8	−37.4%
2021								2.7	-6.0	6.5	-11.6	-19.1	−26.4%

INSD

Insider Activity · CTKB

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Aug 17, 2026	Mccombe William D.Chief Financial Officer	—	35.4K	—
Aug 17, 2026	Muir Glenn PDirector	—	3.1K	—
Aug 17, 2026	Chin Richard M.D. Ph.D.Director	—	6.1K	—
Aug 17, 2026	Holder MichaelDirector	—	2.2K	—
Aug 17, 2026	Jiang WenbinChief Executive Officer	—	120.1K	—
Aug 17, 2026	Yan MingChief Technology Officer	—	33.3K	—
Jun 11, 2026	Yan MingChief Technology Officer	Stock Gift at price 0.00 per share.	135.9K	—
Jun 9, 2026	Imper VeraDirector	—	44K	—
Jun 9, 2026	Neff Deborah JDirector	—	44K	—
Jun 9, 2026	Holder MichaelDirector	—	44K	—
Jun 9, 2026	Ball JackDirector	—	44K	—
May 17, 2026	Mccombe William D.Chief Financial Officer	—	25.7K	—
May 17, 2026	Busque Philippe Ph.D.Officer	—	10.5K	—
May 17, 2026	Chin Richard M.D. Ph.D.Director	—	6.1K	—
May 17, 2026	Holder MichaelDirector	—	1.5K	—
May 17, 2026	Barnett ValerieOfficer	—	24.3K	—
May 17, 2026	Jiang WenbinChief Executive Officer	—	80.1K	—
May 17, 2026	Yan MingChief Technology Officer	—	22.2K	—
Mar 12, 2026	Yan MingChief Technology Officer	Stock Gift at price 0.00 per share.	1.18M	—
Mar 9, 2026	Mccombe William D.Chief Financial Officer	—	23.7K	—

13F

Investors Holding CTKB

latest 13F filings of 29 followed managers

Investors holding CTKB
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$2.9M	0.00%	661.30K	−2.3%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

CTKB

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

CTKB

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Cytek Biosciences, Inc.

Seasonality · CTKB

Insider Activity · CTKB

Congress Trades · CTKB

Investors Holding CTKB

Investors Holding CTKB

Congress Trades · CTKB

Insider Activity · CTKB

Seasonality · CTKB

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Cytek Biosciences, Inc.

Financial Snapshot

Earnings & Dividends

News